Category Archives: News

Opioid Overdoses Costing U.S. Hospitals an Estimated $11 Billion Annually

By | News | No Comments

CHARLOTTE, N.C. -– A recent Premier Inc. (NASDAQ: PINC) analysis found that total care for patients who experienced an opioid overdose resulted in $1.94 billion in annual hospital costs across 647 healthcare facilities nationwide.

Premier®, a healthcare improvement company, found that these costs were concentrated among nearly 100,000 opioid overdose patients with nearly 430,000 total visits across emergency department (ED), inpatient and other care settings. Sixty-six percent of the patients were insured by public programs (33 percent Medicare and 33 percent Medicaid), 16 percent used a commercial payer, 14 percent were uninsured and 3 percent were covered under other programs, such as workers’ compensation.

Annual hospital care for overdose patients represents a significant portion of healthcare expenditures and can be detrimental to providers in regions with high addiction rates. For instance, by extrapolating the cost trends Premier identified in its analysis, the total added costs to the U.S. healthcare system are estimated to amount to $11.3 billion annually, or 1 percent of all hospital expenditures. If the payer mix remained constant, $7.4 billion of the expense would be borne by the federal Medicare and Medicaid programs.

“Opioid addiction has been a public health problem for some time, but we’ve yet to show exactly how hospitals – the entities that treat most of these patients – are financially impacted,” said Roshni Ghosh, MD, MPH, Vice President and Chief Medical Information Officer, Premier. “This analysis shows that on top of losing family members and friends to this epidemic, it’s costing consumers and taxpayers, as well as hospitals. There is an urgent need to provide health systems and emergency caregivers with frontline solutions that they can use to stem the tide of opioid addiction in our communities.”

Leveraging the Premier Healthcare Database, Premier’s analysis of opioid overdose visits, patient progression, and usage and cost patterns was made available to members via individual hospital and system-level reports. These actionable reports are standardized to help health system leaders easily and quickly benchmark internal patterns, relative to opioid overdoses, to measure their performance based on industry trends and pinpoint opportunity areas. The Premier Healthcare Database leverages the PremierConnect® performance improvement platform, which houses data on 45 percent of U.S. patient discharges nationwide.

“The comparative analyses that Premier provides in these reports are key to supporting health system efforts to address this epidemic,” said Ghosh. “These are detailed, evidence-based insights that help providers create focused and customized pain management and addiction reduction initiatives specific to the patients that need them. Our goal is to support our members in every way possible in reducing overuse and misuse, and improving health outcomes, safety and costs at the same time.”

Opioid overdose patients that present to the ED are at a high risk for multiple organ failure, hospitalization, increased costs due to ICU stays and unplanned readmissions following discharge. According to the Premier analysis, caring for all overdose patients treated in the ED alone amounted to more than $632 million in costs to hospitals. Approximately 47 percent of patients were treated and released, and 53 percent were treated and admitted. Of those that were admitted, nearly 40 percent experienced organ failure. The average cost for an overdose patient who was treated and released totaled $504, but the average cost rose to $11,731 for those that were treated and admitted and to $20,500 for those that required ICU care. Adding these costs – ED, inpatient and ICU – totaled the $1.94 billion in annual hospital charges.

While the analysis used the data from 647 facilities to estimate a national aggregate rate (40.9 per 10,000 visits), there was wide state-to-state variation, ranging from a low of 6.1 per 10,000 visits to a high of 87.5 per 10,000 visits. Of those receiving treatment, 34 percent were treated for heroin poisoning and 8 percent were treated for synthetic opioid poisoning, such as methadone. Likewise, 58 percent of those treated were for undetermined opioid poisoning, including prescription opioids and overlapping or unspecified use, such as if the patient used heroin that was laced with synthetics, e.g., fentanyl.

In addition to the added expense of providing care for overdose patients, Premier’s analysis found that three of every 10,000 overdose patients die in the ED, while another 366 per 10,000 patients die in inpatient settings. The impact of an overdose can often be reversed quickly in the ED or by emergency responders. However, overdose patients admitted to the hospital can experience extended lengths of stay and are at risk of mortality depending on the amount and type of drug they took, as well as their current health status. Moreover, of those who were treated and released from the ED, about 24 percent were readmitted for additional emergency care within 30 days of discharge. Therefore, opioid overdose patients are being readmitted at a higher rate than the 17.5 percent national average for 30-day readmissions for Medicare patients, as calculated by the Centers for Medicare & Medicaid Services (CMS).

Premier’s outstanding research and clinical expertise has helped the company build and offer solutions to further aide providers on the frontlines in addressing the opioid epidemic. Premier partners with professional associations and federal agencies to help its members better manage these patients, as well as advocates for changes to regulations and policies that limit care coordination. For example, 30 Premier member health systems recently participated in a national safer post-operative pain management pilot program as part of Premier’s Hospital Improvement Innovation Network, which tested and designed new care delivery processes to better manage pain and the potential for opioid drug addiction. Based on learnings from its members, Premier developed a Safer Pain Management Toolkit, which provides easy-to-access information and an aggregated inventory of products, solutions and resources that support pain management methods to improve patient safety for its members. Additionally, Premier uses its data-driven reports, such as the opioids analysis, to help members pinpoint areas of opportunity and works with them on care transformation strategies to improve performance. Premier’s clinical surveillance solution, powered by TheraDoc®, also provides real-time alerts for pharmacy team interventions on high-risk drugs and potentially dangerous drug combination interactions, as well as monitors patients prescribed high-dose long-acting/extended release opioids.

More information on efforts to address the opioid epidemic can be found on the Premier Safety Institute® website.

Analysis Methodology

The analysis of opioid overdoses and related costs was conducted in October 2018 using the most recent 12 months of data from 647 facilities contained within a database maintained by Premier. In contrast to recent CDC and CMS findings, Premier’s analysis used ICD-10 coded opioid overdoses and clinical presentation in the ED (with subsequent admission for treatment or “treat and release”) and excluded patients who were administered opioid medication by the hospitals themselves. While Premier’s calculated rate (40.9 per 10,000) is significantly higher than some previously reported rates, it better reflects the overall burden on healthcare facilities and private and public payers. The extrapolation analysis leveraged data from the Healthcare Cost and Utilization Project, which estimates 143 million annual ED visits nationwide and applied the 40.9 per 10,000 rate in Premier’s analysis to estimate the number of opioid overdose ED visits annually (584,870 visits nationwide or 5.8 times more). Premier then multiplied the $1.94 billion in annual costs in its analysis by 5.8 to get an estimated $11.3 billion in annual ED costs.

About Premier, Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as TwitterFacebookLinkedInYouTubeInstagram and Premier’s blog for more information about the company.

Premier Inc. Granted ONC Health IT Certification for Antimicrobial Use and Resistance Reporting

By | News | No Comments

Premier’s clinical surveillance solution enables reporting of antimicrobial use and resistance data through the CDC’s National Healthcare Safety Network

CHARLOTTE, N.C. (October 31, 2017) — Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has received certification for antimicrobial use (AU) and antimicrobial resistance (AR) (AUR) reporting under ONC Health IT Certification.

Premier is one of the only companies to have earned official certification from the ONC Health IT Certification Program for the submission of AUR data to the National Healthcare Safety Network (NHSN). These new capabilities are available as part of Premier’s clinical surveillance solution, which has more than 1,100 hospital and health system users. Powered by TheraDoc®, the real-time solution enables clinicians to proactively identify patients at-risk for hospital-acquired infections, harmful drug interactions and other adverse events, as well as meet regulatory reporting compliance and improve medication management to reduce costs and support clinical initiatives.

To ensure quality and timely data submission, Premier’s AUR capabilities provide clinicians detailed reviews of data for validation prior to NHSN submission, automated reporting to meet deadlines and get credit for Meaningful Use Stage 3 (MU3), as well as support efforts to improve antimicrobial stewardship. The goal for AU reporting is to facilitate risk adjusted inter- and intra-facility benchmarking of antimicrobial usage, as well as to evaluate trends of antimicrobial usage over time at the facility and national levels.

“Reducing antimicrobial resistance is a top priority for our hospital and health system members,” said Michelle Allen, vice president of clinical surveillance operations. “We are honored to receive this certification to help Premier members continue to lead the fight against antimicrobial resistance. Our customizable solution not only adheres to MU3 reporting but also gives clinical teams back time so they can focus on delivering high-quality, safe patient care.”

According to the Centers for Disease Control and Prevention, each year at least two million people in the U.S. become infected with bacteria that are resistant to antibiotics and approximately 23,000 people die as a result. A new option to meet public health registry reporting under MU3 incentive payments is AUR submission to the NHSN. This national initiative provides local and regional benchmarks to target antimicrobial stewardship efforts. Vendor certification is a federal requirement for healthcare facility reporting of AUR-MU3 data. To qualify for the 2017 MU3 incentive payment, 90 days of consecutive AUR data must be submitted to the NHSN before the Jan. 31, 2018 deadline.

Premier’s clinical surveillance solution is available through its PremierConnect® performance improvement platform, which integrates clinical, financial and outcomes information on 45 percent of U.S. hospital discharges and $56 billion in annual supply chain purchases. Premier also offers the submission of AUR data as a service to providers without the technology to submit the measures.

About the certification
TheraDoc, version 4.7 certification number is 170021R00. ONC Health IT certification conferred by ICSA Labs does not represent an endorsement of the certified Health IT technology by the U.S. Department of Health and Human Services.
 
For full certification details and disclosures, including any additional types of costs and/or limitations, please visit:  https://www.theradoc.com/certifications/

About Premier Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and more than 150,000 other provider organizations. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on HYPERLINK “http://www.premierinc.com” www.premierinc.com for more information about the company.

CONTACT: Morgan Guthrie, Premier Inc.;
Morgan_Guthrie@PremierInc.com;
704.816.4152

Adventist Health System Expands Partnership with Premier Inc. to Better Treat Diseases

By | News | No Comments

Florida-based health system to employ PremierConnect® pharmacy clinical surveillance and analytics across 40 hospitals to enhance medication management, antibiotic stewardship

CHARLOTTE, N.C. (March 9, 2017) — Adventist Health System, a faith-based healthcare organization headquartered in Altamonte Springs, Florida, has expanded its partnership with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to use pharmacy clinical surveillance and analytics in its effort to better treat diseases.

A member of Premier for more than 20 years, Adventist Health System uses clinical, operational and supply chain analytics in the PremierConnect® performance improvement platform. By expanding its partnership in 40 hospitals across nine states, Adventist Health System will integrate Premier’s pharmacy clinical surveillance and analytics with existing PremierConnect analytics to enhance medication management and antibiotic stewardship.

“Patient safety has always been a top priority at Adventist Health System,” said Loran D. Hauck, MD, chief clinical officer for Adventist Health System. “Premier’s pharmacy clinical surveillance and analytics solution will help our pharmacists forecast and identify opportunity areas, prioritize next steps, document interventions and benchmark progress across the continuum. This is particularly important as we enhance our antimicrobial stewardship program with capabilities to quickly identify situations where antibiotics have no clinical benefit and reduce the emergence of antibiotic resistance.”

PremierConnect pharmacy clinical surveillance and analytics, powered by TheraDoc®, streamline data for pharmacists to target clinical intervention opportunities, track performance with customizable departmental reports and alerts, and optimize drug therapies in real-time. Providers use the solution to create or enhance antimicrobial stewardship programs by identifying cases of antibiotic overuse, reducing time-to-appropriate therapy and enhancing treatments for difficult-to-treat pathogens. Additionally, the solution helps providers adhere to the Centers for Disease Control and Prevention’s National Healthcare Safety Network reporting requirements.

“Adventist Health System is a leading organization that is committed to fostering an environment where patient safety and the efficacious use of life-saving drug therapies is a top priority,” said Leigh Anderson, chief information officer, Premier. “We’re thrilled they chose to build on their relationship with Premier to improve disease treatments and reduce the administrative burden on pharmacists whose time is better spent focusing on delivering safe and effective care.”

The financial terms of the agreement were not disclosed, and are not expected to materially affect Premier’s fiscal 2017 financial results.

About Premier Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 3,750 U.S. hospitals and more than 130,000 other provider organizations. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

Forward-looking statements

Matters discussed in this release that are not statements of historical or current facts, such as  Adventist Health System’s anticipated use of Premier’s performance services at expected levels, as discussed herein, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC and available on Premier’s website at investors.premierinc.com. Forward looking statements speak only as of the date they are made. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date

https://www.premierinc.com/adventist-health-system-expands-partnership-premier-inc-better-treat-diseases/

Morgan Rae Guthrie

Director, Public Relations

Premier Inc.

P: 704.816.4152; C: 704.425.3056

13034 Ballantyne Corporate Place Charlotte, NC 28277

Today, an urgently needed tool was introduced to help US hospitals implement strategies to promote the appropriate, safe use of antibiotics.

By | News | No Comments

Today, an urgently needed tool was introduced to help US hospitals implement strategies to promote the appropriate, safe use of antibiotics. The National Quality Forum (NQF) and the Centers for Disease Control and Prevention (CDC), alongside a team of more than 25 experts, including Premier Inc., convened to create the Antibiotic Stewardship in Acute Care: A Practical Playbook.

Examples of strategies in the Playbook include team-wide, systematic approaches to: assessing when patients need antibiotics and when treatment should be adjusted; educating staff, family, and patients about appropriate antibiotic use; and, tracking and reporting antibiotic prescribing, use, and resistance.

Premier hospital members have been taking steps to combat antibiotic-resistant bacteria. In fact, since the launch of Premier’s nationwide collaborative initiative to improve antibiotic overuse, more hospitals are adopting antibiotic stewardship programs. Premier’s spring Economic Outlook survey suggests 97 percent of health system C-Suite feel that developing/enhancing an antimicrobial stewardship program is a top priority – this is up from 81 percent in the fall.

It has been estimated that up to half of antibiotic use in hospitals is unnecessary and inappropriate. In fact, Premier/CDC research found that 78% of hospitals were overprescribing redundant combinations of intravenous (IV) antibiotics for two or more days. In addition, antibiotic overuse and misuse have spurred the spread of Clostridium difficile infections that can cause life-threatening colitis. In a recent study on the impact of C.difficile, Premier found that the majority of cases analyzed were associated with concomitant antibiotic use.

Premier with its members are committed to reducing HAIs, including those acquired due to antibiotic resistance. To join NQF’s webinar at 1:30 p.m. ET today to launch the Playbook, click here.

Premier, Inc. continues growth trajectory with acquisition of Hospira’s TheraDoc

By | News | No Comments

Premier, Inc. (NASDAQ: PINC) has reached a definitive agreement to acquire TheraDoc, a market leading provider of clinical surveillance software, for $117 million in cash, subject to potential purchase price adjustments regarding TheraDoc’s actual working capital, cash and indebtedness at closing. The transaction is expected to close in Premier’s fiscal 2015 first quarter ending September 30, 2014, subject to customary closing conditions.

TheraDoc is a wholly-owned subsidiary of Hospira (NYSE: HSP). Premier’s board of directors unanimously approved the transaction, and applicable antitrust approvals have already been obtained. Based on the trailing twelve months operating earnings provided by TheraDoc, the $117 million represents a purchase price multiple in the 10-11 times range.

Read More

Hospira’s TheraDoc™ Infection Control Assistant Ranked #1 In Its Category In The Latest “Best In KLAS” Report

By | News | No Comments

LAKE FOREST, Ill., Jan. 23, 2013 – Hospira (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, today announced that its TheraDoc™ Infection Control Assistant™ has been ranked as the top product in the Infection Control & Monitoring software category in the recently released Best in KLAS Awards 2012: Software and Services Report (more information available at www.theradoc.com). The full report is available at www.KLASresearch.com. The rankings are based on data from customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment and infrastructure solutions.

TheraDoc Infection Control Assistant scored the highest overall performance rating in KLAS’ Infection Control & Monitoring market segment, demonstrating excellence and leadership in serving customers and meeting their expectations. TheraDoc also received the highest product quality rating in its category, and the highest customer willingness to repurchase the software again (95 percent).[1]

“Hospira is honored that TheraDoc has been recognized for excellence in infection monitoring and surveillance software,” said France Pitera, vice president, Clinical Information Technology, Hospira. “This recognition is very meaningful since it comes as a direct result of feedback from TheraDoc users. This close working relationship with our users is one key reason why 100 percent of the more than 600 hospitals and healthcare facilities nationwide that have acquired TheraDoc still retain the system today.*”

The TheraDoc clinical surveillance system helps infection preventionists tackle many of their most significant challenges, including time spent on regulatory reporting, time to identification of healthcare-associated infections (HAIs), time to isolation of patients with infectious diseases, and tracking of organism resistance.

“After a thorough review of available systems, we chose TheraDoc to support our Infection Prevention program,” says Peggy Thompson, R.N., B.S.N., C.I.C., director of Infection Prevention at Tampa General Hospital. “It has proven to be an invaluable tool in the ever-changing world of infections and regulatory requirements. TheraDoc staff is receptive and incorporates changes based on feedback from their customers.”

The TheraDoc Infection Control Assistant provides infection preventionists with real-time (a matter of seconds) information needed to make a valid identification of infections, while leaving final determination in the hands of infection preventionists. The Infection Control Assistant also delivers powerful tools enabling infection preventionists to configure workflow to their unique needs, develop their own alerts, select from a large library of existing alerts, and automate creation of reports for the National Healthcare Safety Network.

As part of a suite of knowledge modules that make critical patient information and medical knowledge readily available, the Infection Control Assistant is designed to help clinicians intervene quickly, prescribe appropriately, and improve the quality and safety of patient care.[2],[3] The TheraDoc Clinical Intelligence™ Platform is the engine that powers these software modules, which also include the Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information, visit www.theradoc.com.

KLAS is a research firm specializing in monitoring and reporting on the performance of healthcare vendors. KLAS’ mission is to improve delivery by independently measuring vendor performance for the benefit of its healthcare provider partners, consultants, investors, and vendors. Working together with executives from more than 4,500 hospitals and more than 2,500 clinics, KLAS delivers timely reports, trends, and statistics that provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, medical equipment, and infrastructure vendors.

About Hospira

Hospira, Inc., is the world’s leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.

###

Media
Barbara Sullivan

Sullivan & Associates
(714) 374-6174Tareta Adams
Hospira
(224) 212-2535
Financial Community
Karen King

Hospira
(224) 212-2711Ruth Venning
Hospira
(224) 212-2774

[1] “Best in KLAS Awards 2012: Software and Services Report,” December 2012. © 2012 KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com.

[2] Hellinger W, Alvarez S, Brumble L, Keating M, Mendez J, Darracott R, Young E, Smith R, Mentel J. Optimizing antibiotic therapy with computerized integration of hospital information systems and an antibiotic management team (AMT). Poster session presented at: 42nd Annual Meeting of the Infectious Diseases Society of America; 2004 Sep 30-Oct 3; Boston, MA.

[3] Pass M, Song X, Mackie K, Perl T. Enhanced Isolation Practices To Improve Patient Safety: Preventing Nosocomial Transmission in a Hospital. Am J Infect Control. 2006 June;34(5):E105-E106.